Clinical Trials Search
Clinical Trial 18682
Interventions:Paraplatin (carboplatin); Taxol (paclitaxel); carboplatin; paclitaxel
Study Type: Other
Phase of Study: NA
- Martine Extermann
Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer: Prospective Study of Pharmacokinetics Patterns and Underlying Biology.
While significant progress has been made in the treatment and prognosis of ovarian cancer, this progress has mostly shown benefits for younger women. This study aims to understand two things: How body composition (the amount of muscle and water versus fat in in the body) affects the dose and side effects of chemotherapy; and the biological reason for the worse prognosis with aging. To get a good view of these effects, investigators are asking the help of both younger and older women for this project.
Primary: A.) Assess the correlation of body composition with the AUC of carboplatin and paclitaxel. B.) Correlate body composition and AUC with toxicity from preoperative chemotherapy (CTCAE 4.0), nadir neutrophil counts, and relative dose-intensity (RDI). C.) Assess the association of age with changes in mean values, variance, or strength or correlation under 1A and 1B. Secondary: A.) Assess the correlation with age of gene expression changes in the tumor and its micro-environment before and after neoadjuvant chemotherapy and its correlation with tumor response. B.) Assess the impact of inflammation, as assessed by serum and ascites cytokines on gene expression and response, and its correlation with age. C.) Assess the impact of inflammation on toxicity and RDI. D.) Correlate the above parameters with relapse-free survival (RFS), and overall survival (OS).